*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | Nicotinamide-N-methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model Pharmacological research · preclinical | PMID 40484359 |
| 2024 | Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction Diabetes, obesity & metabolism · preclinical | PMID 39161060 |
| 2023 | Nicotinamide N -methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma Hepatology (Baltimore, Md.) · preclinical | PMID 36633260 |
| 2021 | Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation Molecular metabolism · preclinical | PMID 33453420 |
| 2021 | Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies Journal of pharmaceutical and biomedical analysis · preclinical | PMID 34304009 |
| 2018 | Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice Biochemical pharmacology · preclinical | PMID 29155147 |
| 2009 | Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine Atherosclerosis · preclinical | PMID 18996527 |
5-Amino-1MQ (5-Amino-1-methylquinolinium (NNMT inhibitor)). Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — not a peptide. Preclinically increases cellular NAD+ and SAM, promotes adipocyte energy expenditure and reduces fat mass in obese mice.
Commonly discussed uses: metabolic / fat-loss research (preclinical), muscle-regeneration research. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Note: most uses are not approved indications.
Mechanism: Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — not a peptide. Preclinically increases cellular NAD+ and SAM, promotes adipocyte energy expenditure and reduces fat mass in obese mice.
Reported considerations: no human safety data. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Preclinical small molecule (not a peptide). No human safety data. Not approved. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low research-defined, typical no established human dose; anecdotal 50-150mg unvalidated, high unknown safe ceiling. Administration: oral. Half-life: not characterised in humans.
Australian status: Not ARTG-registered; research. Preclinical small molecule (not a peptide). No human safety data. Not approved. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: oral — no reconstitution; storage: room temp / per product.
Commonly discussed combinations (anecdotal for unapproved compounds): anecdotal metabolic protocols (unvalidated). Stacking increases interaction/safety uncertainty.